Back to top
more

Medtronic (MDT)

(Delayed Data from NYSE)

$92.08 USD

92.08
5,176,270

-0.66 (-0.71%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $92.06 -0.02 (-0.02%) 4:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Abbott Launches Coronavirus Detection Test After FDA Gives EUA

by Zacks Equity Research

Abbott (ABT) launches test for the detection of coronavirus in human, after receiving the EUA.

Zacks Equity Research

Medtronic to Boost Ventilator Capacity to Combat Coronavirus

by Zacks Equity Research

When all other major business segments of Medtronic (MDT) are facing recessionary hurdles, the company's latest move is anticipated to aid its Minimally Invasive Therapies Group business.

Zacks Equity Research

Quest Diagnostic Grows on New Acquisitions Amid Low Volume

by Zacks Equity Research

Quest Diagnostics' (DGX) latest strategic acquisitions act as major growth catalysts.

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

by Urmimala Biswas

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Zacks Equity Research

Here's Why You Should Add Zimmer Biomet to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Zimmer Biomet (ZBH) on its strong segmental and international results in the fourth quarter of 2019.

Zacks Equity Research

Walgreens' Reimbursement Issue Mars Growth, Kroger Pact Aids

by Zacks Equity Research

Persistent reimbursement pressure and adverse mix associated with brand inflation hampers Walgreens' (WBA) bottom-line performance.

Zacks Equity Research

Hologic (HOLX) Gets EUA for Its Coronavirus Detecting Test

by Zacks Equity Research

Hologic (HOLX) receives support from the government as a EUA for its molecular test to detect novel coronavirus on its Panther Fusion system.

Zacks Equity Research

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on its strong segmental and international results in the fourth quarter of 2019.

Zacks Equity Research

QIAGEN's Coronavirus Test Kit Development Gets BARDA Funding

by Zacks Equity Research

QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.

Zacks Equity Research

Walgreens Adopts New Measures to Fight Against Coronavirus

by Zacks Equity Research

Walgreens (WBA) collaborates with industry partners and healthcare administrators to provide greater access to government-run COVID-19 testing facilities.

Zacks Equity Research

National Vision Grows on Positive Comps, Rising Costs a Woe

by Zacks Equity Research

National Vision's (EYE) positive comparable store sales (comps) growth story continues for 72 consecutive quarters.

Zacks Equity Research

Bio-Rad Launches SARS CoV-2 Standard for Coronavirus Testing

by Zacks Equity Research

With the launch of Bio-Rad's (BIO) SARS CoV-2 Standard, it aims to help laboratories validate coronavirus testing and accelerate the access to testing.

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.

Zacks Equity Research

Zimmer Biomet Grows on Strong Emerging Market, Innovation

by Zacks Equity Research

Zimmer Biomet (ZBH) solidifies its foothold in the emerging markets on strong operational and sales performance.

Zacks Equity Research

OrthoPediatrics Announces Latest Screw System Launch in US

by Zacks Equity Research

OrthoPediatrics (KIDS) releases the latest cannulated screw system as part of its beta release to address trauma as well as other bone fixation procedures.

Zacks Equity Research

CVS Health's Schnuck Pharmacy Buyout to Widen Specialty Arm

by Zacks Equity Research

Given the growing prospects of specialty pharmacy, CVS Health (CVS) is prioritizing expansion of this business.

Zacks Equity Research

ResMed (RMD) Grows on SaaS Capabilities Amid Rising Expenses

by Zacks Equity Research

Within SaaS, ResMed (RMD) registers growing momentum in the Brightree service portfolio.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its strong segmental and international results for the fiscal second quarter.

Zacks Equity Research

Henry Schein (HSIC) Expands by Signing JV With Casa Schmidt

by Zacks Equity Research

Henry Schein (HSIC) strengthens position in Spain and Portugal by signing a JV with Casa Schmidt.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

Zacks Equity Research

ZBH or MDT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. MDT: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt

by Urmimala Biswas

S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.

Sreoshi Bera headshot

Robotics & AI Make Inroads in HealthCare: Stocks to Benefit

by Sreoshi Bera

Robotics and AI make rapid advancement in the field of healthcare. Here are five stocks that you can bet on.

Zacks Equity Research

Quest Diagnostics (DGX) to Launch Coronavirus Test Service

by Zacks Equity Research

Quest Diagnostics (DGX) aims to mobilize effective public health response to the coronavirus outbreak through quality laboratory testing.

Zacks Equity Research

CVS Health's Latest Alliances to Fortify Kidney-Care Business

by Zacks Equity Research

With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.